Compounded Tirzepatide: What Changed When the FDA Ended the Shortage

What Is Tirzepatide?

Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management), both made by Eli Lilly. It's a dual GLP-1/GIP receptor agonist — activating two pathways simultaneously — which produced greater average weight loss in clinical trials than GLP-1-only medications.

During a period of high demand and supply shortages, licensed compounding pharmacies were permitted to compound tirzepatide. That period has ended.

Where Things Stand Now

The FDA removed tirzepatide from its official drug shortage list in 2025. With the shortage resolved, the regulatory basis that permitted widespread compounding of tirzepatide under shortage provisions no longer applies. The FDA has actively pursued enforcement against pharmacies continuing to compound it outside of permitted conditions.

Compounding pharmacies may now only prepare tirzepatide for patients with a documented medical necessity — a specific, individualized clinical reason why the commercially available Mounjaro or Zepbound cannot meet the patient's needs. This determination must come from the prescribing physician.

What Qualifies as Medical Necessity?

Medical necessity for a compounded GLP-1/GIP medication is a high clinical bar. Situations that may qualify include:

• A documented allergy to a specific inactive ingredient (excipient) in Mounjaro or Zepbound
• A clinical need for a dose or concentration not available in the FDA-approved products
• A documented reason the standard delivery format cannot be used for a specific patient

Cost alone — even significant cost hardship — does not constitute medical necessity under current FDA guidance. The prescriber must document a clinical, not financial, rationale.

What This Means for Patients

Patients who previously accessed compounded tirzepatide through shortage-based compounding no longer have that pathway broadly available. Those seeking tirzepatide now typically need to obtain Mounjaro or Zepbound through standard channels.

For cost management, Eli Lilly's LillyDirect direct-pay program offers Zepbound at reduced monthly costs for cash-pay patients, and the Zepbound Savings Card can reduce out-of-pocket costs with commercial insurance. Insurance coverage, prior authorization appeals, and patient assistance programs are also worth exploring with your prescriber's office.

If You Do Qualify for Compounded Tirzepatide

For patients with a legitimate documented medical necessity, the pharmacology remains the same — tirzepatide in a compounded preparation activates the same GLP-1 and GIP receptors as Mounjaro. The differences are in delivery format (vial and syringe vs. autoinjector pen) and the quality assurance pathway.

Choosing a 503B outsourcing facility with third-party Certificate of Analysis (COA) testing is especially important for compounded sterile injectables.

Bottom Line

Compounded tirzepatide is no longer widely available following the FDA's resolution of the shortage. Access is now limited to patients with documented medical necessity. If you think you may qualify, work with your prescriber to establish and document the clinical rationale before approaching a compounding pharmacy.